In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sleeping Giant: Europe's Slice of the Global UI Market

Executive Summary

The near-dormant global market for urinary incontinence treatments is poised to erupt in the second half of this decade-Novartis' recent acquisition of Pfizer's darifenacin introduces one more global player to the mix. But for existing and novel drug therapies to succeed in the fragmented and particularly underdeveloped European market companies must first recognize the challenges presented by cultural taboo and country-specific regulation.

You may also be interested in...



Lectus Therapeutics Ltd.

Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.

Mid-sized Players Dining Out on Big Pharma Leftovers

Big Pharmas are beginning to shy away from expensive licensing deals, at least until they begin to see returns on their existing blockbuster agreements. This reluctance is opening the door for mid-sized firms-particularly Europeans-to transform themselves through increased and more creative dealmaking. Moreover, the transition by traditionally in-licensing based firms like Spain's Esteve to out-licensers will accelerate the prominence of Europe's mid-sized players.

ED in Europe: A Rising Tide?

Worldwide launches of new PDE5 inhibitors to treat erectile dysfunction are certain to expand the global market for these and other ED therapies. But in Europe, Viagra's brand ubiquity, the prohibition of DTC advertising, and disparate national markets present challenges to firms hoping to dethrone the Pfizer juggernaut.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel